Background {#Sec1}
==========

Malaria continues to be a significant contributor to the global burden of diseases. Mass administration of antimalarial drug treatments (MDA) to entire populations has been used as an intervention strategy for reducing the global malaria burden \[[@CR1], [@CR2]\], particularly during elimination efforts in the early to mid-twentieth century \[[@CR3]\]. Recently, however, interest in MDA as a viable malaria intervention strategy has reemerged, in particular in conjugation with emergency responses to non-malarial epidemics (e.g., the 2014--2015 Ebola outbreak in West Africa) \[[@CR4]--[@CR7]\] and seasonal malaria chemoprevention in the Sahel region \[[@CR8]\].

Contemporary MDA interventions, primarily through intermittent preventive treatment and seasonal chemoprevention campaigns, have been used to interrupt malaria transmission in low endemicity settings \[[@CR9]\], as well as reduce malaria burden in vulnerable subpopulations, such as young children and pregnant women, in high endemicity settings \[[@CR10], [@CR11]\]. In traditional MDA interventions, all individuals in a population or subpopulation receive treatment regardless of symptoms or other diagnostic information. This approach ensures that all sick individuals receive treatment; however, it also leads to overtreatment, which may increase the overall cost of MDA and undermine resource allocation. Modern antimalarial drugs, such as artemisinin-based combination therapy (ACT), can be expensive and often are in limited supply; therefore, wasting these resources on malaria-negative individuals can be costly \[[@CR12], [@CR13]\]. In addition, the overuse of ACTs can lead to an increase risk of anti-malaria resistance \[[@CR14]\].

An alternative approach to MDA is mass screen and treat (MSAT), which consists of first screening the population with a diagnostic test and then only treating individuals with a positive test outcome. Because microscopic evaluations and molecular techniques (e.g., polymerase chain reaction) are often not a viable option in remote regions and/or at large operational scales, diagnosis is increasingly based on rapid diagnostics tests (RDTs) throughout much of sub-Saharan Africa \[[@CR1], [@CR15]\]. RDT screening has been repeatedly shown to be a viable, cost-effective option for diagnosing malaria \[[@CR16], [@CR17]\]. The widespread use of RDTs has significantly reduced the use of antimalarial drugs, helping to reduce the risk of resistance emergence \[[@CR18], [@CR19]\]. In addition to use of RDT in clinical settings, MSAT relying on RDT outcomes has been shown to be a cost-effective method for reducing malaria burden in certain contexts \[[@CR20]\]. However, determining when and where MSAT will reduce the cost of traditional MDA is an important challenge \[[@CR9]\]. On the one hand, despite the potential of MSAT to reduce costs and overtreatment, there have been notable failures in field studies in terms of ensuring long-term improvements in health and educational indices \[[@CR21], [@CR22]\]. The emergence of resistance is a particularly important concern given the growing consensus that repeated interventions are necessary for sustaining the impact of MDA and MSAT \[[@CR9], [@CR23]--[@CR25]\]. A recent Cochrane review has indicated that 182 studies have assessed the impact of these types of malaria interventions (MDA and its variants, including MSAT) \[[@CR2]\]; however, few guidelines have emerged to help decision-makers determine when MSAT is a more cost-effective strategy than MDA \[[@CR26]--[@CR29]\]. In general, MSAT is thought to be the preferred approach in high- to mid-transmission settings \[[@CR30]\], which was supported by the study from Crowell et al. \[[@CR3]\]. In contrast, however, Walker et al. \[[@CR31]\] found that MDA was more cost-effective than MSAT in all but the highest transmission settings, and noted that the slight cost deficit in these areas was likely offset by the additional period prophylaxis provided to post-intervention infected individuals \[[@CR32]\]. Gerardin et al. \[[@CR33]\], on the other hand, argued that in control/pre-elimination settings, the cost of overtreatment by MDA may mitigate the detection advantage (i.e., ensuring all infected individuals are treated) and therefore undermine the cost-effectiveness of MDA compared to MSAT. Corroborating these findings with field research has been difficult, as much of the observed data on recent MDA and MSAT applications is held in gray literature and unpublished reports \[[@CR2], [@CR9]\].

Multiple factors can influence the costs of MSAT relative to MDA. For example, unlike MDA, inaccurate diagnostic results in MSAT can lead to both overtreatment and undertreatment. Although RDTs have high overall sensitivity (above 93%) and specificity (above 95%), a comprehensive review of field studies found substantial heterogeneity in RDT performance \[[@CR34]\]. Additionally, the detection mechanism differs among different types of RDTs. For example, commonly used HRP2-based RDTs such as Paracheck® will fail to detect infections caused by non-*Plasmodium falciparum* species or by *P. falciparum* parasites which carry mutations to the HRP-2 gene, resulting in false negative results \[[@CR35], [@CR36]\]. False positive results can also be an issue, as the HPR-2 protein can persist in the host for up to 2 to 3 weeks after parasitemia has cleared \[[@CR36]\]. Ultimately, the potential cost-savings advantage of MSAT over MDA depends on baseline likelihood of infection (i.e., prevalence), RDT sensitivity and specificity, the costs of treatment and RDTs, and the costs associated with false positive and false negative results \[[@CR33], [@CR37]\]. However, many of these factors can vary substantially within sub-Saharan countries \[[@CR34], [@CR37]\], and as a result, it can be difficult to generalize which strategy is likely to reduce implementation costs in each country/region \[[@CR38]\]. Nevertheless, identifying the local optimal strategy is important for stakeholders and policy implementers as national malaria control programs move away from a "one-size-fits-all" approach.

In this article, we outline a conceptual framework for comparing the cost of malaria intervention strategies based on the probability of their possible outcomes and the costs associated with those outcomes, focusing on the comparison between MDA and MSAT. First, we demonstrate this comparative framework using hypothetical scenarios for each of these factors. Next, we create probabilistic models for estimating malaria prevalence and RDT performance using routinely collected national-scale survey data (e.g., Demographic Health Surveys (DHSs) and Malaria Indicator Surveys (MISs)) to present a real-world application. Finally, using these models, we build an interactive web application which allows end-users to compare the expected intervention costs in each region within each country based on the inputted economic values, thereby extending these models into decision support tools which allow implementers to interact with the data and models directly.

Methods {#Sec2}
=======

Estimating intervention costs {#Sec3}
-----------------------------

The expected cost per person associated with MDA and MSAT interventions can be estimated as a function of the costs of implementing these interventions, the costs associated with the potential outcomes, and the probability of those outcomes. The possible outcomes for an individual participant in an MDA campaign are either true positive or false positive, whereas an individual participant in an MSAT campaign may also be true negative or false negative (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Conceptual framework for costs of mass drug administration (MDA) and mass screen and treat (MSAT). Flow diagram based on the potential outcomes and associated costs for each intervention. Testing and outcome costs are shown in blue and red, respectively. FP and FN stand for false positive and false negative, respectively

To determine the probability of each of these potential outcomes, we calculate the likelihood of malaria infection *p*(*M* = 1), the sensitivity *p*(RDT = 1 \| *M* = 1), and specificity *p*(RDT = 0 \| *M* = 0) of the screening diagnostic test (model variables are defined in Table [1](#Tab1){ref-type="table"}). In this framework, testing costs refer to materials used by the intervention (e.g., RDT, treatment with an ACT), and outcome costs refer to additional costs related to outcomes from the intervention (e.g., additional healthcare costs due to a false negative RDT results). Cost items include cost of the diagnostic test used for screening (Cost~RDT~), the cost of antimalarial treatment (Cost~Trt~), and the outcome costs of false negatives (Cost~FN~) and false positives (Cost~FP~). Notice that the outcome costs of false negative or false positive diagnostic outcomes may incorporate multiple sources of cost (i.e., lost wages due to illness, deleterious impact of side effects, increased risk of antimalarial resistance) and that these costs may occur at varying levels of the overall healthcare system (e.g., provider costs, individual costs, societal costs). The per-person expected cost of MDA is given by: $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
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The per-person expected cost of MSAT is given by: $$\documentclass[12pt]{minimal}
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This framework could be augmented through the inclusion of additional layers of complexity, such as the inclusion of overall program-level costs and/or an expanded set of possible outcomes (e.g., likelihood of developing severe malaria and the associated costs), if data on these costs and outcomes were available. We elected to develop this individual-level framework which includes productivity losses, but note that it can be readily extended to more complex data and applications such as designating societal and healthcare provider costs.

We used this framework to compare the potential cost of MDA and MSAT in two contexts. In the generalized comparisons, we compare costs across all possible baseline prevalence. The sensitivity, specificity, and costs of RDTs were based on a recent report from the WHO \[[@CR26]\] and make comparisons using hypothetical scenarios based on differing costs associated with false negative and false positive outcomes (Table [2](#Tab2){ref-type="table"}). In the context-specific comparisons, we use publically available data to construct models for estimate baseline prevalence as well as RDT sensitivity and specificity, and apply similar scenario-based comparisons. Table 2Diagnostic performance and costs (in USD) used for baseline comparison*Diagnostic accuracy* RDT sensitivity^\*^0.82 to 0.96 RDT specificity^\*^0.80 to 0.90*Healthcare provider costs (USD)* Cost of RDT^\*^0.60 Cost of treatment (ACT)^\*^2.40*Societal costs (USD)* Lost daily wages^†^21.55*Scenario costs* ScenarioFalse negativesFalse positives  A. No cost associated with false positive or false negative0.000.00  B. False negative equal to cost of RDT^\*^2.400.00  C. False negative equal to cost of RDT^\*^ and potential lost wages^†^23.950.00  D. Same as C with small offset for false positives23.951.50\*Based on \[[@CR26]\]^†^Based on \[[@CR39]\]

Modeling outcome probability based on prevalence, sensitivity, and specificity {#Sec4}
------------------------------------------------------------------------------

### Description of the data used for modeling {#Sec5}

Information on malaria status of children 5 years old and under was sourced from Demographic and Health and Malaria Indicator Surveys (DHS and MIS, respectively). These data are freely available, use standardized sampling procedures, and contain information on a broad range of malaria indicators, such as age, urbanicity, and fever history. Recent surveys were selected for Burkina Faso \[[@CR40]\], Cote d'Ivoire \[[@CR41]\], Ghana \[[@CR42]\], Guinea \[[@CR43]\], Nigeria \[[@CR44]\], and Togo \[[@CR45]\]. For each survey, the data are reported at the first order civil entity below the country level (commonly referred to as "administrative area 1"). The official names for these areas vary between countries; therefore, we adopt the term "regions" throughout the article for clarity. Note that this means that "regions" are operationally defined as sub-areas within individual countries. These West African countries were selected because they each contain relatively recent standardized country-wide surveys and included information on RDT and microscopy (assumed to be the "gold standard" in this region \[[@CR46], [@CR47]\]). The RDTs used in these are surveys are specific to *Plasmodium falciparum*, which account for the vast majority of malarial infections in this region. Individual survey sample sizes ranged from 2713 to 6112 individuals, distributed across 6 to 13 regions per country (Table [3](#Tab3){ref-type="table"}). Table 3Summary of data sourcesCountrySurvey typeCollection periodSample sizeRegionsBurkina FasoMalaria Indicator Survey \[[@CR48]\]September 2014--November 2014611213Cote d'IvoireDemographic Health Survey \[[@CR49]\]December 2011--May 2012334411GhanaDemographic Health Survey \[[@CR50]\]September 2014--December 2014271310GuineaDemographic Health Survey \[[@CR51]\]June 2012--October 2012319811NigeriaMalaria Indicator Survey \[[@CR52]\]October 2015--November 201551276TogoDemographic Health Survey \[[@CR53]\]November 2013--April 201432156

### Modeling prevalence, sensitivity, and specificity {#Sec6}

Malaria prevalence and diagnostic performance were estimated separately for each country using Bayesian mixed-effect logistic regression models. Microscopy (*M*) was considered the "gold standard" for detecting malaria infections in this region \[[@CR46], [@CR47]\], and RDT (*R*) was considered the screening diagnostic test. Let *M*~*ijk*~ represent the binary infection status (as determined by microscopy) of individual *i* from cluster *j* in region *k*. We assume that *M*~*ijk*~ is given by: $$\documentclass[12pt]{minimal}
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                \begin{document}$$ {M}_{ijk}\mid {p}_{ijk}\sim \mathrm{Bernouli}\left({p}_{ijk}\right) $$\end{document}$$where *p*~*ijk*~ is the probability of infection (e.g., prevalence). We constructed the model using just two basic covariates that could be relevant for the development of region-specific policy, namely age in months (Age~*ijk*~) and a binary classification of urban/rural environment (Urban~*jk*~) based on the survey's definition (see references in Table [3](#Tab3){ref-type="table"}). Using the logit link function $\documentclass[12pt]{minimal}
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This equation includes a cluster-level random-effect intercept *a*~*jk*~, regional-level fixed-effects (i.e., intercepts *β*~0,\ *k*~ and slopes *β*~1,\ *k*~ and *β*~2,\ *k*~), and country-level fixed-effects (i.e., country-level slopes *β*~3~ and urbanicity *β*~4~).

In relation to RDT, let *R*~*ijk*~ represent the binary test outcome (1 for positive, 0 for negative) of individual *i* from cluster *j* in region *k*. We assume that: $$\documentclass[12pt]{minimal}
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                \begin{document}$$ {R}_{ijk}\mid {M}_{ijk}=0,{Sp}_{ijk}\sim \mathrm{Bernouli}\left(1-{Sp}_{ijk}\right) $$\end{document}$$where *Sn*~*ijk*~ and *Sp*~*ijk*~ denote the RDT sensitivity and specificity, respectively. Both parameters were modeled with the same set of predictor variables and link function as *p*~*ijk*~.

Individual models for prevalence, sensitivity, and specificity were created for each country using the "brms" package in the open-source R statistical software \[[@CR48], [@CR49]\]. We adopted the recommended priors based on our model specification (flat priors for the fixed effects, and half Student's *t* with 3 degrees of freedom and a scaling factor of 1 for the standard deviation of the random effects) \[[@CR49]--[@CR51]\]. Due to the large sample size in our data, these priors play very little to no role in influencing our results. The fully specified model with the full posterior is described in Supplemental Material [1](#MOESM1){ref-type="media"}. Each model was fitted using a Hamiltonian Monte Carlo with 4 independent chains, each containing a 1000-iteration burn-in phase and a 1000-iteration sampling phase, resulting in 4000 posterior samples. Parameter convergence was determined using the potential scale reduction factor (convergence at $\documentclass[12pt]{minimal}
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                \begin{document}$$ \hat{R}<1.05 $$\end{document}$) \[[@CR52]\].

Designing the interactive framework {#Sec7}
-----------------------------------

Based on the outlined cost functions and associated outcome probabilities, we developed an interactive framework which allows users to compare the relative costs of MDA and MSAT in each region (as defined by DHS/MIS) within each country. This was done using the "shiny" package in R \[[@CR53]\], a package that enables the creation of web-based interactive applications directly from R code (instead of HTML, CSS, or JavaScript), which can then be freely hosted and accessed on the Internet. Web applications like this can facilitate engagement with stakeholders and policymakers with limited statistical and programming backgrounds. Examples of other epidemiological interactive tools developed in Shiny can be found in \[[@CR54]--[@CR57]\].

By using probabilistic models for specifying the outcome probabilities, we are able to compare intervention scenarios while incorporating uncertainty. Aside from inputting cost values, the interface allows users to select covariate values (i.e., country, age range, and urbanicity), which then results in an update of the cost comparison in real time. We used the "leaflet" package in R to create an interactive map-based visualization of the cost comparison \[[@CR58]\]. The code used to create this tool is available at <https://github.com/justinmillar/mda-msat>. We also constructed a "generalized" version of the application, which allows the user to specify a range for RDT sensitivity and specificity and compare MDA versus MSAT over all possible prevalence rates (rather than estimating these parameters from data).

Results {#Sec8}
=======

General comparisons {#Sec9}
-------------------

Using general cost and diagnostic accuracy parameters from the WHO \[[@CR26]\] (Table [2](#Tab2){ref-type="table"}), MSAT is preferred in nearly all but the highest disease burden settings when the cost of false negatives is ignored (Fig. [2](#Fig2){ref-type="fig"}a). However, the costs associated with MSAT increase in higher prevalence scenarios once the cost of false negatives is assumed to be equal to the cost of treatment (e.g., an RDT-negative individual eventually receives treatment; cost of \$2.40 \[[@CR26]\]) (Fig. [2](#Fig2){ref-type="fig"}b). The individual-level cost of MSAT can be further undermined if the overall economic burden of false negative includes additional costs. To demonstrate this, if we assume a scenario where a person whose child has a false negative result also incurs a day of lost wages (cost of \$23.95, based on hourly rate and assuming 8 h per workday based on the median monthly income in sub-Saharan from World Bank estimates \[[@CR39]\]), in order to take their child to a health facility to receive care, then screen and treat yields a significantly higher costs (Fig. [2](#Fig2){ref-type="fig"}c). Note that this is just one potential scenario where the cost of a false outcome can drastically shift the associated costs. Other scenarios, such as a false negative leading to a severe malaria infection, could decrease the benefit of MSAT. Finally, the primary effect of including a cost associated with false positive is raising the cost of MDA treatment in lower burden settings, which is eventually offset by costs associated with misdiagnosis in the screen-and-treat scenario as prevalence increases (Fig. [2](#Fig2){ref-type="fig"}d). Fig. 2Costs of mass drug administration (MDA) and mass screen and treat (MSAT) based on malaria prevalence. Each panel depicts a different scenario relative to the costs associated with false positive (FP) and false negative (FN) outcomes, as specified in the legends. The lower estimated cost (*y*-axis) indicates which strategy will have lower associated costs for a given prevalence rate (*x*-axis). RDT sensitivity and specificity ranged from 0.82 to 0.96 and 0.80 to 0.90, respectively, and the cost of treatment and RDT were set to \$2.40 and \$0.60, based on a WHO report \[[@CR26]\]. The gray-shaded region indicates overlap in expected cost, where the more favorable strategy is unclear due to the range of possible values for RDT sensitivity and specificity

In the following section, we present similar scenario-based realizations using the models fit with national survey data. These scenarios represent just a small subset of all the possible scenarios. We believe this demonstrates the utility of using interactive decision support tools, which can re-create cost comparisons based on user-defined scenarios. Also note that these models are fit using data from young children (6 to 59 months old), and therefore, the displayed results are related to this particular subpopulation.

Context-specific observations based on national-scale survey data {#Sec10}
-----------------------------------------------------------------

Individual models for malaria prevalence and RDT sensitivity and specificity rates for young children were fitted for all six country datasets. In each model, all parameters reached convergence based on the potential scale reduction factor (all $\documentclass[12pt]{minimal}
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                \begin{document}$$ \hat{R} $$\end{document}$ values ranged between 0.999 and 1.012). Details on each model are provided in Supplemental Material [1](#MOESM1){ref-type="media"}, and the regional prevalence, sensitivity, and specificity estimates are provided in Supplemental Material [2](#MOESM2){ref-type="media"}. The following sections illustrate the influence of the regression parameter estimates, cost scenarios, and parameter uncertainty on the cost comparison using survey data from Burkina Faso as a representative example.

### Effect of false negatives {#Sec11}

Designating costs specifically related to incorrect diagnostic results can have profound impacts on the cost of the MSAT. Consider the rural communities in Burkina Faso (Fig. [3](#Fig3){ref-type="fig"}), which fall within the mid- to high-transmission setting where MSAT is considered to be viable and potentially cost-effective relative to MDA, and where both clinical trials and mathematical studies have examined the effectiveness of MSAT \[[@CR22], [@CR24], [@CR59]\]. We chose a favorable cost setting for MSAT by setting RDT cost to \$0.60 and antimalarial treatment cost to \$2.55. These costs correspond to the lower and higher ends of RDT and antimalarial prices, respectively, based on a recent WHO report \[[@CR26]\]. Figure [3](#Fig3){ref-type="fig"}a shows the estimated value added from screening per individual for rural communities in Burkina Faso assuming no cost associated with false negatives or false positives. As expected, we find that under these conditions, MSAT is favored in most regions in Burkina Faso, and there are no regions that favor MDA. However, MSAT becomes relatively more costly once we attribute cost to false negative outcomes. When the cost of false negatives is set to the cost of the antimalarial treatment, which corresponds to a scenario where all truly infected individuals will eventually pay to receive treatment, MSAT becomes less favorable. MSAT is only favored in three regions (which had relatively low prevalence and higher sensitivity), and there are more regions where MDA may be more favorable or there is little expected cost difference between MDA and MSAT (Fig. [3](#Fig3){ref-type="fig"}b). MSAT becomes relatively more costly as the cost associated with false negatives increases. Under the hypothetical scenario where a false negative also incurs a lost 1 day's wage based on the minimum wage in Burkina Faso (\$6.37 per day, based on \[[@CR39]\]), MDA is favored in all but two regions, despite relatively high prevalence rates (ranging from 0.26 (CI 0.18--0.36) to 0.66 (CI 0.53--0.77)) (Fig. [3](#Fig3){ref-type="fig"}c). Fig. 3Value added from screen then treat among rural communities in Burkina Faso. Regional maps of the mean value added (i.e., MDA costs minus MSAT costs) and boxplots of value added estimates are shown on the left and right panels, respectively. Positive values (blue) indicate regions where MSAT is favored whereas negative values (red) indicate regions where MDA is favored. Whiskers in boxplots indicate 95% credible intervals. When these intervals contain both positive and negative values, there is no significant difference regarding costs between strategies (gray). Cost of diagnostic test (RDT) and treatment were set at \$0.60 and \$2.55, respectively. **a** Added value estimates ignoring any potential costs associated with false negative results. **b** Value added estimates when cost associated with false negative results is set to the cost of receiving delayed treatment. **c** Value added estimates when cost associated with false negative results includes the cost of receiving delayed treatment and 1 day of lost wage (based on minimum wage \[[@CR39]\]). In all of these scenarios, we assume no cost associated with false positive outcomes

### Differences between urban and rural communities {#Sec12}

As outlined earlier, there are many factors which influence malaria prevalence and RDT performance, and therefore may influence the costs of MDA and MSAT. One factor that strongly determines these variables is the differences between urban and rural communities. Although there is considerable regional-level variability in malaria prevalence within rural communities in Burkina Faso, rural communities consistently have higher prevalence than their urban counterparts (Fig. [4](#Fig4){ref-type="fig"}). Regional RDT sensitivity and specificity rates also consistently decline from rural to urban communities (see \[[@CR34]\] for RDT performance on varying baseline prevalence). These differences between urban and rural communities can affect the costs of both intervention strategies. Figure [5](#Fig5){ref-type="fig"} depicts the same cost scenarios as Fig. [3](#Fig3){ref-type="fig"} for both rural and urban communities in Burkina Faso. These comparisons generally indicate that higher prevalence rural communities will tend to favor MSAT while lower prevalence urban communities tend to favor MDA, although these comparisons greatly depend on cost assumptions. The Nord region was the only region where both urban and rural communities favored MSAT in all cost scenarios. Interestingly, this was not linked to the regional prevalence rates, which were not too different from the other regions (0.16 and 0.47 for urban and rural communities, respectively), but instead were associated with having the highest sensitivity and specificity rates for both community types. This result suggests that even under a cost scenario which strongly favors one approach (in this case MDA), there was still a region where MSAT was favored, which highlights the importance of diagnostic accuracy in assessing costs at the country level. Fig. 4Comparison of regional-level differences of malaria prevalence and RDT sensitivity and specificity in Burkina Faso for urban and rural areas. Mean value estimate (circles) and 95% credible interval (vertical bars) for each region are based on 1000 posterior draws from each model. Each region has a unique shade and is connected by a dotted line to depict differences in parameter estimates between urban and rural communitiesFig. 5Urban versus rural comparison of value added from screen then treat in Burkina Faso. Comparison of regional value added (per individual) from diagnostic screening (MDA costs minus MSAT costs) between urban (left plots) and rural (right plots) communities. Positive values (blue) favor MSAT, negative values (red) favor MDA, and 95% interval ranges that contain both positive and negative values indicate no significant difference (gray). Cost of diagnostic test (RDT) and treatment were set at \$0.60 and \$2.55, respectively. **a** Added value estimates ignoring any potential costs associated with false negative results. **b** Value added estimates when cost associated with false negative results is set to the cost of receiving delayed treatment. **c** Value added estimates when cost associated with false negative results includes the cost of receiving delayed treatment and 1 day of lost wage (based on minimum wage \[[@CR39]\]). In all of these scenarios, we assume no cost associated with false positive outcomes

### Estimating regional breakpoints for treatment and RDT costs {#Sec13}

In addition to comparing the costs of MDA and MSAT directly based on specific values for the direct costs of treatments and diagnostic tests, it may also be valuable to identify the breakpoints for these costs. For example, under different scenarios of false positive and false negative costs, we can use the estimated regional malaria prevalence, RDT sensitivity, and RDT specificity to determine the cost of RDT and treatment for which MDA (or MSAT) would reduce costs. Figure [6](#Fig6){ref-type="fig"} illustrates this using the scenarios in the previous examples for Burkina Faso, assuming no cost associated with false negatives (Fig. [6](#Fig6){ref-type="fig"}a) and including loss of 1 day's wage in the cost associated with false negatives (Fig. [6](#Fig6){ref-type="fig"}b). Notice that as expected, for a given cost of RDT, the cost comparison will tend to favor MSAT as the price of treatment increases. Similarly, for a given cost of treatment, MDA is favored as RDT cost increases. This breakpoint tends to be lower in rural communities, which typically have higher prevalence rates, and increases when we include costs associated with false negative results. For example, the dashed vertical and horizontal lines demonstrate this relationship using the RDT and treatment cost for the previous example (\$0.60 and \$2.55, respectively). Based on these costs, MDA will be favored in most rural districts whereas MSAT may be favored in the urban communities for some districts. These figures illustrate the critical role of the ratio of treatment cost and screening cost in comparing the costs of these interventions and that regional characteristics (prevalence and diagnostic test performance) strongly mediate the relationship between this cost ratio and differences in intervention costs. For example, the Hauts-Bassins region is highlighted to demonstrate how including an outcome cost associated with false negative results in a substantial shift towards favoring MSAT. Fig. 6Regional breakpoints for cost of treatment and diagnostic test (RDT) in Burkina Faso. Cost points above the line favor MSAT in that region, whereas cost points below the line favor MDA. Rural and urban communities are depicted on the left and right columns, respectively. **a** No cost associated with false negative results. **b** A cost associated with false negative results which includes the cost of 1 day of lost wages (based on minimum wage \[[@CR39]\]). Each line represents a different region, and the blue line emphasizes the Hauts-Bassins region. In all of these scenarios, we assume no cost associated with false positive outcomes

Interactive applications {#Sec14}
------------------------

The application based on the "[General comparison](#Sec9){ref-type="sec"}" section is available at <https://jjmillar.shinyapps.io/msat-general/>. Following the conceptual framework (Fig. [1](#Fig1){ref-type="fig"}), this tool allows the user to set the costs of treatment and diagnostic test (RDT), the costs of false positive and false negative outcomes, and a range for the potential diagnostic sensitivity and specificity. The tool relies on these user-defined inputs to estimate the cost of MDA and MSAT across all possible prevalence, generating an output similar to the plots in Fig. [3](#Fig3){ref-type="fig"}. The application based on the data from national surveys and modeling outcomes from prevalence, sensitivity, and specificity is available at <https://jjmillar.shinyapps.io/msat-example/>. This tool allows the user to select the country and setting (e.g., age range and urban or rural communities), as well as the same cost parameters in the first tool. The outputs are similar to the comparisons shown in Figs. [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, and [6](#Fig6){ref-type="fig"}.

Discussion {#Sec15}
==========

As described in the comprehensive review by Newby et al. \[[@CR9]\], many studies have been published on the impact and effectiveness of MDA and MSAT. Implementation of both interventions has experienced both successes and failures. Moreover, simulations based on mathematical models comparing the costs of MDA and MSAT have in some cases provided conflicting recommendations \[[@CR3], [@CR31]--[@CR33]\]. Rather than using mathematical models, our contribution to this important question of resource allocation focuses on using statistical models to quantify the likelihood of different outcomes associated with each intervention. In addition, we use these statistical models to power interactive decision support tools, in which users set the cost parameters and interact directly with inference from our statistical models in an open-source, cross-platform format.

We have prioritized a methodology that would be maximally flexible and accessible, including using familiar publicly available data and relying on relatively simple statistical models and tools developed in open-source and free software. There are, however, several notable limitations associated with these data. First, in order to model malaria status and diagnostic sensitivity and specificity, we assumed microscopy to be the gold standard. While microscopy is considered to be the gold standard in western sub-Saharan Africa \[[@CR46], [@CR47]\], it has been well established that microscopy-based diagnoses are imperfect \[[@CR47], [@CR60], [@CR61]\] and that several factors (e.g., parasite density) can influence the accuracy of microscopy \[[@CR62]\]. Additionally, while microscopy prevalence and RDT prevalence are strongly correlated, other research on DHS data has shown that this relationship is not always linear and that there are additional factors (such as the proportion of febrile individuals) that can influence this relationship \[[@CR63]\]. By using microscopy as a gold standard, our analysis also ignores submicroscopic infections, which typically improve the cost-effectiveness of MDA relative to MSAT. Submicroscopic infections can be significant reservoirs for sustaining transmission; however, they are most impactful in older populations in low-transmission settings and elimination-phase interventions \[[@CR24], [@CR64], [@CR65]\], rather than young children in endemic settings. We believe that data on more precise diagnostic tests (such as polymerase chain reaction) should be used if they were available at national scales. Our methodology can easily be modified to produce better estimates of RDT sensitivity and specificity that accounts for submicroscopic infection, leading to improved cost comparisons.

Second, the approach for estimating costs of MDA and MSAT presented in this article is intentionally simplistic because data that would support a more comprehensive national-level analysis for multiple West African countries were not available. For instance, in addition to the individual-level costs, there are also fixed programmatic-level costs of implementing each intervention, which are unlikely to be equivalent for MDA and MSAT (e.g., RDT-based intervention required additional training and storage). Furthermore, we discuss the individual-level cost of receiving the intervention, but do not take into account how these interventions influence morbidity/mortality metrics (e.g., disability-adjusted life-year). Including data on incremental outcomes would allow for comparing effectiveness, rather than just overall costs. In particular, determining which metric to use for the cost-effectiveness comparison is important for defining the goal of the intervention (e.g., interrupting transmission or reducing malaria burden). We also note that the simplified cost analysis relying on productive losses may disproportionally favor MSAT in some of the hypothetical scenarios. More detailed cost analyses, including stratified cost sources, are still needed and may yield different results to the hypothetical scenarios used to demonstrate the framework. These could be implemented by designing additional compartments to the cost components in Table [1](#Tab1){ref-type="table"}.

Finally, if national-level data on malaria prevalence and RDT performance were available for febrile patients seeking help at health facilities, tools like the one described in this article could be developed for clinical settings to determine where and when test and treat would be a better option than presumptive treatment. In this case, one could also account for other potential outcomes, such as developing severe malaria (which may have a much higher associated cost), not adhering to a diagnostic test result, and the development of adverse side effects to treatment. Such a tool may be useful for improving adherence to national policies regarding treatment protocols \[[@CR66]--[@CR68]\].

The WHO recently identified a pressing need for modeling-based approaches to guide the selection of optimal interventions under different epidemiological conditions \[[@CR69]\]. Decision support tools designed specifically for malaria control, particularly using mapping approaches and geostatistical models, have become more prevalent in recent years as national survey data have become more broadly accessible \[[@CR70]--[@CR73]\]. Our framework aims to provide a decision support tool for stakeholders for comparing costs associated with MDA or MSAT in different regions. We have demonstrated that such tools can be created and adapted using a standard, open-source program, helping to bridge the gap between methodological advancements and real-world decision-making. This is an important extension, as traditional scientific articles are often not an effective way to communicate the practical implications of complex analysis to policymakers \[[@CR74]\]. These decision support tools are critically important as national malaria control programs have identified the need to move away from "one-size-fits-all" intervention and require tools for identifying optimal interventions based on location-specific conditions \[[@CR75]\]. The applications presented in this article contribute to the growing pool of decision support tools for guiding malaria control interventions.

Similar to the work by Lubell et al. \[[@CR70]\], one valuable characteristic of the support tool presented is interactivity. Standard results presented in scientific articles are limited to the parameters or scenarios selected by scientists, which often do not necessarily match those that would have been chosen by decision-makers. Furthermore, often, decision-makers must consider additional information that is either unknown or unaccounted for by the original developer, which is only possible if users can explore different scenarios within the decision support tool. However, similar to using statistical models without understanding their underlying assumptions, decision support tools can be prone to misinterpretation if not carefully designed and described \[[@CR76]\]. Furthermore, important properties of the tools presented in this article are that they rely solely on a freely available open-source program, can be hosted on web applications (which makes them platform-independent), and can be completely built using software regularly used in epidemiological research. Finally, by using a Bayesian framework for modeling the data and enabling user-defined inputs for cost parameters, our application allows stakeholders to make informed decisions while taking into account uncertainty in the outcomes under different cost scenarios.

Conclusion {#Sec16}
==========

We present a flexible framework for comparing the cost of MDA and MSAT and use this framework along with publicly available malaria data from national-scale surveys to construct an interactive decision support tool. The methodology used to create this tool addresses critical issues (e.g., cross-platform, open-source, real-time interactivity) with previous decision support tools for guiding malaria interventions and can be built using widely used open-source software. The tool provides a platform for decision-makers (who may not have a strong statistical background) to interact with statistical models and adjust the parameters to fit their context and external knowledge in order to support data-driven decision-making. We believe that similar decision support tools designed to fit specific malaria interventions and contexts will be valuable assets for guiding data-driven decision-making for malaria control and elimination in a way that recognizes the inherent differences between regions.
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